

New American Economy Trust

Series 13

A 2 Year Unit Investment Trust

The New American Economy

The way in which humans and businesses operate and interact continues to evolve, and that rate of change has never been quicker. This evolution has occurred in areas including technology, health care and commerce. Furthermore, the pandemic caused by the novel form of coronavirus disease first detected in 2019 ("COVID-19") triggered a societal and economic paradigm shift that may last for decades.

We believe the already rapid evolution taking place, combined with the force of change brought on by the COVID-19 pandemic, has formed the basis of a new American economy.

Strategy Background

We sought to provide total return potential through capital appreciation and dividend income by identifying innovative and quality U.S. companies with the potential to thrive in the new American economy. We chose to focus on the thematic areas of Health Care, Technology and E-Commerce in an effort to find proven leaders and innovators that will likely continue that trend in the new American economy.

Selection Process

Starting Universe



In selecting the portfolio for the trust, we applied various screens and considered the following factors, among others:

- Analyst Coverage & Ratings
- Earnings
- Valuation
- Profitability
- Financial Strength
- Dividends

Final Portfolio of 30 Stocks

Sales Charges and Estimated Expenses¹

(Based on a \$10 public offering price)

Standard Accounts	Transactional Sales Charge:	Initial	0.000%
		Deferred	2.250%
	Creation & Development Fee: ²		0.500%
	Maximum Sales Charge:		2.750%
	Estimated Organization Costs: ³		0.542%
	Estimated Annual Operating Expenses: ⁴		0.207%

The initial sales charge is paid at the time of purchase and is the difference between the total sales charge (maximum of 2.75% of the public offering price) and the sum of the remaining deferred sales charge and the total creation and development fee. When the public offering price per unit is less than or equal to \$10, you will not pay an initial sales fee. When the public offering price per unit is greater than \$10 per unit, you will pay an initial sales fee.

The deferred sales charge is a charge of \$0.225 per unit and will be deducted in three monthly installments commencing on March 20, 2027. The initial and deferred sales fees do not apply to fee-based accounts. Please see the prospectus for sales charge details.

Fee/Wrap Accounts	Creation & Development Fee: ²	0.500%
	Maximum Sales Charge:	0.500%
	Estimated Organization Costs: ³	0.542%
	Estimated Annual Operating Expenses: ⁴	0.207%

¹Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

²The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%.

³Estimated Organization Costs are assessed on a fixed dollar amount per unit basis of \$0.0542 per unit and may be less than estimates. For additional information on organization costs please see the prospectus.

⁴Estimated Annual Operating Expenses include fees for administration, bookkeeping, the trustee, the supervisor and acquired fund fees and expenses. This expense is an estimate based upon an estimated trust size. If the trust does not reach or falls below the estimated size, the actual amount of the operating expenses as a % of unit price may exceed the amount reflected. Please see "Trust Expenses and Charges" in the trusts prospectus for additional information.

Investors should consider the trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the trust. Please read the prospectus carefully before you invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

Hennion & Walsh is a member of FINRA/SIPC. 2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 (888) 505-2872 www.smarttrustuit.com
NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE

Description of Portfolio

INCEPTION DATE:	September 10, 2026
TERMINATION DATE:	September 12, 2028
INITIAL OFFER PRICE	\$10.00
MINIMUM INVESTMENT	100 units (may vary by selling firm)
NUMBER OF ISSUES:	30
DISTRIBUTIONS: ⁵	MONTHLY (if any)
HISTORICAL 12-MONTH DISTRIBUTION: ⁶	\$0.0535 (per unit)
CUSIP (CASH):	83208K 143
CUSIP (REINVESTMENT):	83208K 150
FEE-BASED CUSIP (CASH):	83208K 168
FEE-BASED CUSIP (REINVESTMENT):	83208K 176
TICKER:	STNAMX


⁵Distributions, if any, will be made commencing on October 25, 2026.

⁶The Historical 12-Month Distribution of Trust Holdings is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust's portfolio over the 12 months preceding the trust's date of deposit reduced to account for the effects of trust fees and expenses. This historical distribution is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust. The distributions paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future.

Portfolio Holdings as of September 10, 2026:

EQUITY SECURITIES – 100.00%			
Communication Services – 10.19%		ETON	Eton Pharmaceuticals, Inc.
GOOGL	Alphabet Inc.	GILD	Gilead Sciences, Inc.
META	Meta Platforms, Inc.	HQY	HealthEquity, Inc.
QNST	QuinStreet, Inc.	JNJ	Johnson & Johnson
Consumer Discretionary – 6.76%		MRK	Merck & Co., Inc.
Consumer Staples – 3.37%		Information Technology – 40.11%	
AMZN	Amazon.com, Inc.	ATEN	A10 Networks, Inc.
GOLD	Gold.com, Inc.	ADI	Analog Devices, Inc.
WMT	Walmart Inc.	ANET	Arista Networks, Inc.
Financials – 6.43%		BDC	Belden Inc.
MA	Mastercard Incorporated	AVGO	Broadcom Inc.
V	Visa Inc.	DDOG	Datadog, Inc.
Health Care – 33.14%		LRCX	Lam Research Corporation
ABBV	AbbVie Inc.	MRVL	Marvell Technology, Inc.
CAH	Cardinal Health, Inc.	MU	Micron Technology, Inc.
CRVS	Corvus Pharmaceuticals, Inc.	MITK	Mitek Systems, Inc.
CVS	CVS Health Corporation	MSI	Motorola Solutions, Inc.
LLY	Eli Lilly and Company	NVDA	NVIDIA Corporation

Portfolio Allocation as of September 10, 2026:



Risk Considerations

Unitholders can lose money by investing in this trust. An investment in units of the trust should be made with an understanding of the risks related to the trust, such as the following:

- Security prices will fluctuate. The value of your investment may fall over time. Market values of securities held by the trust may fluctuate in response to various factors. These can include changes in interest rates, inflation, the financial condition of a security's issuer, perceptions of the issuer, adverse events impacting a particular industry or sector and/or significant events impacting the entire securities market. The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your units. A drop in credit rating generally indicates an increased likelihood of an issuer's risk of default on a loan. Where an issuer's credit rating is decreased, the perceived financial health of the company, the perceived value of the company and the corresponding market value of its equity securities will generally decrease. This may occur at any point in time, including during the initial offering period.
- An issuer may be unable to make interest and/or principal payments in the future. This may reduce the level of income the trust receives which would reduce your income and cause the value of your units to fall.
- An issuer may be unwilling or unable to declare dividends in the future or may reduce the level of dividends declared. This may reduce the level of income the trust receives which would reduce your income and cause the value of your units to fall. It is also possible that current or future government aid programs could limit companies from paying dividends as a condition to receiving government aid or discourage companies from doing so.
- The trust invests significantly in E-Commerce companies as defined above. E-Commerce companies are generally subject to the risks of rapidly changing technologies; short product life cycles; fierce competition; aggressive pricing; frequent introduction of new or enhanced products and services; the loss of patent, copyright and trademark protections; cyclical market patterns; evolving industry standards; decreased demand for new equipment; decreased demand for freight and logistics services; occupancy and rent levels of real estate; and frequent new product and service introductions. Negative developments in E-Commerce companies and related industries will affect the value of your investment more than would be the case in a more diversified investment.
- The trust is considered to be concentrated in securities issued by companies in the health care and information technology sectors. Negative developments in these sectors may affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include the impacts of existing and changing government regulations and spending, increasing competition from new products or services, loss of patent and other intellectual property protection and substantial research and development costs. General risks of companies in the information technology sector include rapidly changing technologies, short product life cycles, frequent introduction of new or enhanced products, the impacts of existing and changing government regulations, and the loss of patent and other intellectual property protections.
- The portfolio includes equity securities issued by operating companies in the health care sector. Negative developments in this sector may affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include the impacts of existing and changing government regulations and spending, increasing competition from new products or services, loss of patent and other intellectual property protection and substantial research and development costs.
- The trust may invest in stocks of small and mid-size companies. These stocks are often more volatile and have lower trading volumes than stocks or larger companies. Small and mid-size companies may have limited products or financial resources, management inexperience and less publicly available information.
- The trust is not actively managed. Except in limited circumstances, the trust will hold, and continue to buy, shares of the same securities even if their market value declines.
- The sponsor may offer successive trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive trusts, if available. There may be tax consequences associated with investing in the trust and rolling over an investment from one trust to the next.